CardioSignal is a health technology company developing groundbreaking solutions for early detection of heart diseases. We are based in Turku, Finland and Palo Alto, CA, United States. The CardioSignal mobile application is a CE-marked class IIa medical device for the detection of atrial fibrillation, available in over 10 countries. The technology we are developing enables a digital cardiac biomarker for other major heart diseases as well.
CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology is built on a decade of research and algorithm development.
Our purpose
We are supporting healthcare in battling the #1 killer of people in the world. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world.
Early identification and treatment of heart disease, such as atrial fibrillation, would help prevent strokes and heart attacks and improve outcomes for individuals and society.
CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology is built on a decade of research and algorithm development.
Our purpose
We are supporting healthcare in battling the #1 killer of people in the world. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world.
Early identification and treatment of heart disease, such as atrial fibrillation, would help prevent strokes and heart attacks and improve outcomes for individuals and society.
Location: Finland, Mainland Finland, Turku
Employees: 11-50
Total raised: $10M
Founded date: 2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.01.2024 | Series A | $10M | - |
Mentions in press and media 10
| Date | Title | Description |
| 12.11.2024 | Maki.vc Ignites Innovation with €100 Million Fund | In the heart of Helsinki, a financial spark has ignited. Maki.vc, a venture capital firm, has launched its third fund, a robust €100 million, aimed at fueling the engines of pre-seed and seed-stage startups across the Nordics and Northern E... |
| 12.11.2024 | Maki.vc launches €100M Fund for Pre-Seed and Seed-stage startups | Helsinki-based venture capital firm Maki.vc has launched its third fund of €100 million to invest in Pre-Seed and Seed-stage startups across the Nordics and Northern Europe. Maki.vc’s first and second funds have helped propel a number of hi... |
| 14.05.2024 | How Maki VC is driving change in startup investments: a look at its 2023 Sustainability Report | Helsinki’s Maki VC is a deeptech VC that invests in early-stage companies from their inception to Series Seed and beyond. It primarily focuses on the Nordics but selectively invests across Northern Europe, with investments in startups from ... |
| 10.04.2024 | New App Detects Heart Failure Through Built-in Sensors in Your Smartphone | Jace Dela Cruz, Tech Times 10 April 2024, 05:04 am A new technology developed by the University of Turku and CardioSignal utilizes a smartphone's built-in sensors to analyze heart movement and potentially detect heart failure, a condition a... |
| 24.01.2024 | Finnish healthtech CardioSignal raises $10M in Series A funding | Finnish healthtech CardioSignal raises $10M in Series A funding 24 January, 2024, 09:31 Mariia Denysiuk --> --> --> -->--> --> --> --> --> --> --> --> --> CardioSignal has announced the closing of a... |
| 24.01.2024 | CardioSignal secures $10M Series A for industry-first smartphone tech for heart disease detection | Medtech company CardioSignal this week announced the closing of $10 million in Series A funding. CardioSignal develops digital technologies and software-as-medical-devices to provide early detection of heart diseases, and provides the first... |
| 24.01.2024 | Smartphone-based heart exam developer CardioSignal collects $10M | CardioSignal, the developers of an app that performs a heart test using some of the most basic smartphone features, has collected $10 million in early venture capital funding to validate its approach in the clinic. CardioSignal’s software u... |
| 23.01.2024 | CardioSignal scores $10M for heart disease detection technology | Photo: d3sign/Getty Images |
| 23.01.2024 | CardioSignal Raises $10M in Series A Funding | CardioSignal, a Turku, Finland- and Palo Alto, CA-based provider of solutions for the detection of heart diseases using digital cardiac biomarkers, raised $10M in Series A funding. The round, which brought the total amount to $23M, was led ... |
| - | CardioSignal | “Access information about your heart health in just one minute using your phone.” |